Zacks Investment Research downgraded shares of Eidos Therapeutics (NASDAQ:EIDX) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning, Zacks.com reports.

According to Zacks, “Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States. “

A number of other research firms have also recently commented on EIDX. BMO Capital Markets initiated coverage on Eidos Therapeutics in a research report on Friday, February 22nd. They set an outperform rating and a $28.00 target price on the stock. ValuEngine cut Eidos Therapeutics from a buy rating to a hold rating in a research report on Monday, December 17th. Finally, JPMorgan Chase & Co. upgraded Eidos Therapeutics from a neutral rating to an overweight rating in a research report on Wednesday, February 27th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. Eidos Therapeutics has an average rating of Buy and a consensus price target of $27.00.

EIDX opened at $23.79 on Tuesday. Eidos Therapeutics has a one year low of $8.89 and a one year high of $24.75.

In other news, CFO Christine Siu sold 11,913 shares of Eidos Therapeutics stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $19.66, for a total transaction of $234,209.58. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

A number of hedge funds have recently modified their holdings of the stock. BlackRock Inc. increased its position in Eidos Therapeutics by 57.9% in the 4th quarter. BlackRock Inc. now owns 1,149,364 shares of the company’s stock valued at $15,814,000 after acquiring an additional 421,666 shares during the period. Aisling Capital Management LP acquired a new position in Eidos Therapeutics in the 4th quarter valued at about $15,461,000. Redmile Group LLC increased its position in Eidos Therapeutics by 354.3% in the 3rd quarter. Redmile Group LLC now owns 867,700 shares of the company’s stock valued at $8,660,000 after acquiring an additional 676,700 shares during the period. American International Group Inc. acquired a new position in Eidos Therapeutics in the 3rd quarter valued at about $2,393,000. Finally, Victory Capital Management Inc. acquired a new position in Eidos Therapeutics in the 4th quarter valued at about $2,835,000. Hedge funds and other institutional investors own 30.15% of the company’s stock.

About Eidos Therapeutics

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

Read More: Percentage Gainers

Get a free copy of the Zacks research report on Eidos Therapeutics (EIDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Eidos Therapeutics (NASDAQ:EIDX)

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.